Select Language
DRD1
DRD1 Overview
| English Name | Dopamine D1 receptor | Approved Drugs | 9 |
| Drugs in Clinical Trials | 18 | Target Synonym | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Highest Development Stage | Approved | ||
| English Name | Dopamine D1 receptor |
| Target Synonym | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Approved Drugs | 9 |
| Drugs in Clinical Trials | 18 |
| Highest Development Stage | Approved |
DRD1 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
- (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
DR1-H52P6 |  Human | HEK293 | Human DRD1 Full Length Protein (VLP) |  |  Add to Cart |
Total: 1
- 1
DRD1 Background
The dopamine receptor D1 (Drd1) is a member of the D1-like receptor family and is the most abundant dopamine receptor in the central nervous system. The receptor is found in the cortex, striatum and limbic system of the brain and the cardiovascular system.
DRD1 Synonyms
DRD1,Dopamine D1 receptor,D1R; DADR; DRD1A
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering | Details |
| Tavapadon | CVL-751; PF-6649751; PF-06649751 | Phase 3 Clinical | Pfizer Inc, Cerevel Therapeutics Llc | Renal Insufficiency; Parkinson Disease; Hepatic Insufficiency | Details |
| Thioridazine | TP-21 | Phase 3 Clinical | Novartis Pharma Ag | Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular | Details |
| Olanzapine long acting injectable (Teva Pharmaceutical Industries) | TV-44749; TEV-‘749; mdc-TJK; TEV-749 | Phase 3 Clinical | Medincell SA | Schizophrenia | Details |
| Olanzapine/samidorphan (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Schizophrenia | Details | |
| PF-06412562 | PF-6412562; PF-06412562 | Phase 2 Clinical | Pfizer Inc | Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease | Details |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease; Parkinson Disease; Lewy Body Disease | Details |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | Details | |
| Razpipadon | CVL-871 | Phase 2 Clinical | Pfizer Inc | Dementia | Details |
| UCB-0022 | UCB-0022 | Phase 2 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | Details |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | Details | |
| asenapine schizophrenia (Livzon Pharmaceutical/LTS Lohmann Therapie-Systeme) | Phase 1 Clinical | Lts Lohmann Therapie-Systeme Ag | Schizophrenia | Details | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | Details |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | Details | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Pain; Mood Disorders; Opioid-Related Disorders | Details |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | Details | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | United States | Bipolar Disorder | Eli Lilly And Company | 2003-12-24 | Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant | Details |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Schizophrenia; Bipolar Disorder | Details | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | Details | ||||||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Bipolar I Disorder; Alcoholism | Details |
| Olanzapine | ALKS-7921; LY-170052; LY-170053; INP-105; BR-5402 | Approved | Eli Lilly And Company | Zyprexa Zydis, Olanzapine ODF, 再普乐, Midax, Lanzac, Zypadhera, Zalasta, Zyprexa, Zyprexa Velotab, Zyprexa Relprevv, Olansek | EU | Bipolar Disorder; Schizophrenia | null | 1996-09-27 | Emergence Delirium; Chemotherapy-induced nausea and vomiting; Anorexia Nervosa; Fasting; Cachexia; Borderline Personality Disorder; Gambling; Nausea; Bipolar II Disorder; Depressive Disorder, Treatment-Resistant; Vomiting; Malaria, Falciparum; Multiple Myeloma; Bipolar I Disorder; Postoperative Nausea and Vomiting; Feeding and Eating Disorders; Solid tumours; Autistic Disorder; Insulin Resistance; Anorexia; Neoplasms; Opioid-Related Disorders; Bipolar Disorder; Depression; Esophageal Neoplasms; Depressive Disorder, Major; Stomach Neoplasms; Schizophrenia; Substance-Related Disorders; Weight Loss; Hematopoietic stem cell transplantation (HSCT); Biliary Tract Neoplasms | Details |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | Details | ||||||
| Olanzapine/Hydroxyzine pamoate | Approved | Nausea | Details | |||||||
| Stepholidine | Approved | Mainland China | Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders; Headache | null | 1995-01-01 | Migraine Disorders; Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland